Startseite>>Signaling Pathways>> Proteases>> ACE>>Temocapril HCl

Temocapril HCl (Synonyms: CS 622)

Katalog-Nr.GC17034

Temocapril HCl ist ein oral wirksamer Hemmer des Angiotensin-Converting-Enzyms (ACE).

Products are for research use only. Not for human use. We do not sell to patients.

Temocapril HCl Chemische Struktur

Cas No.: 110221-44-8

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
31,00 $
Auf Lager
5mg
27,00 $
Auf Lager
10mg
43,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Temocapril Hydrochloride is a long-acting angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension. Target: ACETemocapril hydrochloride is a novel prodrug-type angiotensin-I converting enzyme (ACE) inhibitor, lowering of the dose of temocapril might be recommended only in patients with severe renal insufficiency [1]. Temocapril is regarded as an ACE inhibitor the disposition and efficacy of which are little affected in patients with impaired liver function [2].

References:
[1]. Nakashima, M., et al., Pharmacokinetics of temocapril hydrochloride, a novel angiotensin converting enzyme inhibitor, in renal insufficiency. Eur J Clin Pharmacol, 1992. 43(6): p. 657-9.
[2]. Furuta, S., et al., Pharmacokinetics of temocapril, an ACE inhibitor with preferential biliary excretion, in patients with impaired liver function. Eur J Clin Pharmacol, 1993. 44(4): p. 383-5.

Bewertungen

Review for Temocapril HCl

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Temocapril HCl

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.